First-line treatment with trastuzumab deruxtecan plus capecitabine and bevacizumab in patients with HER2-positive metastatic colorectal cancer: the CHIMERA study
CLINICAL TRIAL WITH MEDICINES
Clinical trial information
- Promoter: FONDAZIONE GONOONLUS
- Phase: II
- Execution start: 02/07/2025
- End of execution: 30/12/2029
- IP: ENCARNA GONZALEZ FLORES
